A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Walking to Defeat MND with Zakhia
As Zakhia Aoun and her family joined the crowd at Walk to Defeat MND Sydney in 2008, for the first time they were surrounded by others who deeply unde...
Blackshaw Belconnen Bowls Day
Get keen to hit the green - the annual Blackshaw Belconnen Bowls Day is back in 2026, and this year they’ll be supporting MND NSW! Blackshaw Belconnen...
Provide your feedback about disaster preparedness, response and recovery
We are pleased the NSW Reconstruction Authority is seeking feedback from the MND community in the development of their Disability Inclusion Actio...
How an Occupational Therapist can Help People with MND
Occupational Therapy Week is celebrated from 26 October to 1 November and acknowledges the vital contribution that these allied health professionals p...